4
Changes in Ownership
Prelude Therapeutics Inc Filed Acc 0001562180-24-008565
Chief Chemistry Officer bought 63,075 shares at an average $1.36 ($85,538)
From the SEC's structured data for this filing
Trades in this filing
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Combs Andrew Chief Chemistry Officer | 2024-12-20 | Purchase | +3,075 | $1.15 | $3,536 | 317,623 | D |
| Combs Andrew Chief Chemistry Officer | 2024-12-23 | Purchase | +60,000 | $1.37 | $82,002 | 377,623 | D |
| Open-market purchases · 63,075 sh · avg $1.36 · $85,538 | |||||||
Loading xslF345X05/primarydocument.xml…